Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: glutathione Clear all
Active, not recruiting Phase 3 Interventional

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

NCT06859788
View directory record Official record
Conditions
Meniere's Disease, Ménière's Disease
Interventions
Ebselen
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Boynton Beach, Florida • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 3:56 PM EDT
Not listed Phase 2 Interventional

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

NCT00323583
View directory record Official record
Conditions
Adenocarincoma of Pancreas, Stage III Pancreatic Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer
Interventions
paclitaxel, oxaliplatin, leucovorin, 5-fluorouracil, glutathione, calcium and magnesium, Chemotherapy, Chemoprotection, Complementary and alternative therapy
Drug · Procedure
Lead sponsor
Seattle Cancer Treatment and Wellness Center
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2007 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Results available

Glutamine and Insulin Sensitivity in Type I Diabetes

NCT01467063
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Glutamine, Placebo
Dietary Supplement
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional

Biological Evaluation of Dietary Supplement Liposomal Glutathione

NCT01967667
View directory record Official record
Conditions
Schizophrenia
Interventions
Liposomal glutathione, Placebo
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function

NCT04672447
View directory record Official record
Conditions
Menopause, Cardiovascular Risk Factor
Interventions
L-Citrulline, Placebo, Glutathione
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
50 Years to 79 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 22, 2026, 3:56 PM EDT
Recruiting Phase 1 Interventional

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

NCT07050173
View directory record Official record
Conditions
Repetitive Head Impacts
Interventions
Gamma-glutamylcysteine (GGC)
Drug
Lead sponsor
Pravat Mandal
Other
Eligibility
30 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Results available

Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers

NCT00287365
View directory record Official record
Conditions
Mild Asthma
Interventions
ozone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 22, 2026, 3:56 PM EDT
Terminated Phase 2 Interventional

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 2 Interventional

EPI-743 in Friedreich's Ataxia Point Mutations

NCT01962363
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
EPI-743
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 22, 2026, 3:56 PM EDT
Terminated No phase listed Observational

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Mutation, NFE2L2 Gene Mutation
Interventions
Not listed
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 4 Interventional

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NCT02505477
View directory record Official record
Conditions
Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type
Interventions
N-acetylcysteine, Treatment as Usual
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

NCT02583672
View directory record Official record
Conditions
Gaucher Disease Type 1
Interventions
N-acetylcysteine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

NCT01251315
View directory record Official record
Conditions
Oxidative Stress
Interventions
Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Balanced Salt Solution During Cataract Surgery

NCT05853978
View directory record Official record
Conditions
Fuchs Dystrophy, Cataract
Interventions
BSS Plus, BSS
Drug
Lead sponsor
Adam Fedyk, MD, FACS
Other
Eligibility
22 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

NCT01265563
View directory record Official record
Conditions
Diabetic Nephropathy, Proteinuria, Oxidative Stress
Interventions
N-acetylcysteine placebo and silibin placebo, N-acetylcysteine active and silibin placebo, N-acetylcysteine placebo and silibin active, N-acetylcysteine active and silibin active, N-acetylcysteine active + high-dose silibin active
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 76 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional

Treating Oxidative Stress and the Metabolic Pathology of Autism

NCT00572741
View directory record Official record
Conditions
Autistic Disorder
Interventions
B12, Placebo, folate, B complex, vitamin C, cod liver oil, Mineral complex, carnitine
Dietary Supplement
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
3 Years to 7 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 22, 2026, 3:56 PM EDT
Withdrawn Not applicable Interventional

Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients

NCT07553520
View directory record Official record
Conditions
Glioblastoma Multiforme, Recurrent Glioma
Interventions
Normal diet, Cysteine/methionine deprivation (CMD) diet for 2 days, Cysteine/methionine deprivation (CMD) diet for 4 days
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 3:56 PM EDT
Recruiting Phase 1 Interventional

Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study

NCT07304440
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
Biological · Drug
Lead sponsor
Adia Med of Winter Park LLC
Other
Eligibility
3 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Winter Park, Florida • Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 3:56 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

NCT01422486
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
ezatiostat hydrochloride (Telintra®)
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

SPI-1005 for the Treatment of Meniere's Disease

NCT04677972
View directory record Official record
Conditions
Meniere Disease, Ménière
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Roseville, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Phase 2 Interventional

Glutathione (GSH) In The Treatment of Parkinson's Disease

NCT01177319
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Glutathione
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 22, 2026, 3:56 PM EDT
Recruiting Phase 2 Interventional

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

NCT05266417
View directory record Official record
Conditions
Parkinson Disease
Interventions
INS-GSH, Matched Placebos
Drug
Lead sponsor
Gateway Institute for Brain Research
Industry
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 3:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis

NCT00227058
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Orotic acid and Glutathione-(Nutritional Supplements)
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 22, 2026, 3:56 PM EDT
Not listed Phase 2Phase 3 Interventional

Cysteine Supplementation in Critically Ill Neonates

NCT00254176
View directory record Official record
Conditions
Sepsis, Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Retinopathy of Prematurity, Systemic Inflammatory Response Syndrome
Interventions
Parenteral cysteine-HCl supplementation, Placebo - added premasol
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 30 Days
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2010 · Synced Oct 22, 2026, 3:56 PM EDT